New Shot-Based myeloma combo aims to simplify treatment for older patients
NCT ID NCT05889221
First seen May 02, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests a new way to give the drug isatuximab—as a quick shot under the skin instead of a long IV drip—for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. About 74 participants aged 65 and older will receive the shot along with three standard chemotherapy drugs. The goal is to see if this easier-to-take combination works as well as the current IV version in controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Poitiers
Poitiers, 86000, France
Conditions
Explore the condition pages connected to this study.